The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival

Cell Death and Differentiation

Volumn 17, Issue 4, 2010, Pages 666-676

  Kang, R ^a   Tang, D ^a   Schapiro, N E ^a   Livesey, K M ^a   Farkas, A ^a   Loughran, P ^a   Bierhaus, A ^b   Lotze, M T ^a   Zeh, H J ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Apoptosis; Autophagy; Chemotherapy; HMGB1; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; BECLIN 1; CASPASE 3; HIGH MOBILITY GROUP B1 PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MELPHALAN; OXALIPLATIN; PROTEIN P53;

ANIMAL CELL; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL SURVIVAL; CELL VIABILITY; CELLULAR STRESS RESPONSE; CONTROLLED STUDY; CYTOTOXICITY TEST; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; METABOLIC STRESS; MOUSE; NONHUMAN; PANCREAS TUMOR; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; TUMOR CELL;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; CARCINOMA; CELL LINE, TUMOR; CELL SURVIVAL; HMGB1 PROTEIN; HUMANS; INFLAMMATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; MICE; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, IMMUNOLOGIC; RNA INTERFERENCE; STRESS, PHYSIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA; MAMMALIA;

EID: 77949542302     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2009.149     Document Type: Article

References (48)

1. DeNardo DG, Johansson M, Coussens LM. Inflaming gastrointestinal oncogenic programming. Cancer Cell 2008; 14: 7-9.
2. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-867.
3. Logsdon CD, Fuentes MK, Huang EH, Arumugam T. RAGE and RAGE ligands in cancer. Curr Mol Med 2007; 7: 777-789.
4. Abe R, Yamagishi S. AGE-RAGE system and carcinogenesis. Curr Pharm Des 2008; 14: 940-945.
5. Fuentes MK, Nigavekar SS, Arumugam T, Logsdon CD, Schmidt AM, Park JC et al. RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways. Dis Colon Rectum 2007; 50: 1230-1240.
6. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 2001; 50: 2792-2808.
7. Liliensiek B, Weigand MA, Bierhaus A, Nicklas W, Kasper M, Hofer S et al. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 2004; 113: 1641-1650.
8. Soro-Paavonen A, Watson AM, Li J, Paavonen K, Koitka A, Calkin AC et al. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 2008; 57: 2461-2469.
9. Chavakis T, Bierhaus A, Nawroth PP. RAGE (receptor for advanced glycation end products): a central player in the inflammatory response. Microbes Infect 2004; 6: 1219-1225.
10. Turovskaya O, Foell D, Sinha P, Vogl T, Newlin R, Nayak J et al. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis 2008; 29: 2035-2043.
11. Gebhardt C, Riehl A, Durchdewald M, Nemeth J, Furstenberger G, Muller-Decker K et al. RAGE signaling sustains inflammation and promotes tumor development. J Exp Med 2008; 205: 275-285.
12. Taguchi A, Blood DC, del TG, Canet A, Lee DC, Qu W et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000; 405: 354-360.
13. Hiwatashi K, Ueno S, Abeyama K, Kubo F, Sakoda M, Maruyama I et al. A novel function of the receptor for advanced glycation end-products (RAGE) in association with tumorigenesis and tumor differentiation of HCC. Ann Surg Oncol 2008; 15: 923-933.
14. Arumugam T, Ramachandran V, Logsdon CD. Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models. J Natl Cancer Inst 2006; 98: 1806-1818.
15. Logsdon CD, Fuentes MK, Huang EH, Arumugam T. RAGE and RAGE ligands in cancer. Curr Mol Med 2007; 7: 777-789.
16. Gu H, Yang L, Sun Q, Zhou B, Tang N, Cong R et al. Gly82Ser polymorphism of the receptor for advanced glycation end products is associated with an increased risk of gastric cancer in a Chinese population. Clin Cancer Res 2008; 14: 3627-3632.
17. Dong XE, Ito N, Lotze MT, Demarco RA, Popovic P, Shand SH et al. High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother 2007; 30: 596-606.
18. Ito N, DeMarco RA, Mailliard RB, Han J, Rabinowich H, Kalinski P et al. Cytolytic cells induce HMGB1 release from melanoma cell lines. J Leukoc Biol 2007; 81: 75-83.
19. Bopp C, Bierhaus A, Hofer S, Bouchon A, Nawroth PP, Martin E et al. Bench-to-bedside review: the inflammation-perpetuating pattern-recognition receptor RAGE as a therapeutic target in sepsis. Crit Care 2008; 12: 201.
20. Levine B. Cell biology: autophagy and cancer. Nature 2007; 446: 745-747.
21. Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 2008; 4: 151-175.
22. Tanida I, Ueno T, Kominami E. LC3 and autophagy. Methods Mol Biol 2008; 445: 77-88.
23. Mizushima N, Yoshimori T. How to interpret LC3 immunoblotting. Autophagy 2007; 3: 542-545.
24. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999; 285: 1733-1737.
25. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002; 110: 163-175.
26. Peterson RT, Beal PA, Comb MJ, Schreiber SL. FKBP12-rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions. J Biol Chem 2000; 275: 7416-7423.
27. Bartling B, Hofmann HS, Weigle B, Silber RE, Simm A. Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma. Carcinogenesis 2005; 26: 293-301.
28. Rosner M, Siegel N, Valli A, Fuchs C, Hengstschlager M. mTOR phosphorylated at S2448 binds to raptor and rictor. Amino Acids 2009. DOI 10.1007/s00726-008-0230-7.
29. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124: 471-484.
30. Kihara A, Kabeya Y, Ohsumi Y, Yoshimori T. Beclin-phosphatidylinositol 3-kinase complex functions at the trans-Golgi network. EMBO Rep 2001; 2: 330-335.
31. Yousefi S, Perozzo R, Schmid I, Ziemiecki A, Schaffner T, Scapozza L et al. Calpain-mediated cleavage of Atg5 switches autophagy to apoptosis. Nat Cell Biol 2006; 8: 1124-1132.
32. Arumugam T, Simeone DM, Van GK, Logsdon CD. S100P promotes pancreatic cancer growth, survival, and invasion. Clin Cancer Res 2005; 11: 5356-5364.
33. Huttunen HJ, Fages C, Kuja-Panula J, Ridley AJ, Rauvala H. Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res 2002; 62: 4805-4811.
34. Takada M, Hirata K, Ajiki T, Suzuki Y, Kuroda Y. Expression of receptor for advanced glycation end products (RAGE) and MMP-9 in human pancreatic cancer cells. Hepatogastroenterology 2004; 51: 928-930.
35. Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004; 303: 1010-1014.
36. Morselli E, Tasdemir E, Maiuri MC, Galluzzi L, Kepp O, Criollo A et al. Mutant p53 protein localized in the cytoplasm inhibits autophagy. Cell Cycle 2008; 7.
37. Tasdemir E, Maiuri MC, Galluzzi L, Vitale I, Djavaheri-Mergny M, D Amelio M et al. Regulation of autophagy by cytoplasmic p53. Nat Cell Biol 2008; 10: 676-687.
38. Crighton D, Wilkinson S, OPrey J, Syed N, Smith P, Harrison PR et al. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 2006; 126: 121-134.
39. Mathew R, Karantza-Wadsworth V, White E. Role of autophagy in cancer. Nat Rev Cancer 2007; 7: 961-967.
40. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008; 132: 27-42.
41. Fujii S, Mitsunaga S, Yamazaki M, Hasebe T, Ishii G, Kojima M et al. Autophagy is activated in pancreatic cancer cells and correlates with poor patient outcome. Cancer Sci 2008; 99: 1813-1819.
42. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008; 132: 27-42.
43. Yousefi S, Perozzo R, Schmid I, Ziemiecki A, Schaffner T, Scapozza L et al. Calpain-mediated cleavage of Atg5 switches autophagy to apoptosis. Nat Cell Biol 2006; 8: 1124-1132.
44. Zeh 3rd HJ, Lotze MT. Addicted to death: invasive cancer and the immune response to unscheduled cell death. J Immunother 2005; 28: 1-9.
45. Tang D, Kang R, Xiao W, Wang H, Calderwood SK, Xiao X. The anti-inflammatory effects of heat shock protein 72 involve inhibition of high-mobility-group box 1 release and proinflammatory function in macrophages. J Immunol 2007; 179: 1236-1244.
46. Tang D, Shi Y, Jang L, Wang K, Xiao W, Xiao X. Heat shock response inhibits release of high mobility group box 1 protein induced by endotoxin in murine macrophages. Shock 2005; 23: 434-440.
47. Tang D, Kang R, Xiao W, Jiang L, Liu M, Shi Y et al. Nuclear heat shock protein 72 as a negative regulator of oxidative stress (hydrogen peroxide)-induced HMGB1 cytoplasmic translocation and release. J Immunol 2007; 178: 7376-7384.
48. Tang D, Kang R, Xiao W, Zhang H, Lotze MT, Wang H et al. Quercetin prevents lipopolysaccharide-induced HMGB1 release and proinflammatory function. Am J Respir Cell Mol Biol 2009. doi:10.1165/rcmb.2008-0119OC.